Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are trading higher 1.5 percent to $49.86 after Citigroup added the stock to the U.S. focus list and raised the price target to $60 from $56.
Analyst Liav Abraham believes the shares offer the “most attractive risk-reward profile amongst multinational generics universe.”
The “resilience” of Teva's Copaxone, “commercial potential of the pipeline (particularly the respiratory and NTE portfolio), and optionality for increased net cost savings, as sufficient to drive further upside from current levels,” said Abraham.
The analyst's investment thesis is “not predicated on the need for M&A.”
Abrahams $60 price target is based on a “2015e earnings multiple of 13x, vs the peer group average of 13.6x.”
Latest Ratings for TEVA
|Jan 2017||Bank of America||Upgrades||Neutral||Buy|
|Jan 2017||JP Morgan||Downgrades||Overweight||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.